The estimated Net Worth of Vijay B Samant is at least $1.76 Milhão dollars as of 31 August 2020. Mr. Samant owns over 609 units of Brickell Biotech Inc stock worth over $46,248 and over the last 21 years he sold BBI stock worth over $252,411. In addition, he makes $1,464,000 as Director at Brickell Biotech Inc.
Vijay has made over 49 trades of the Brickell Biotech Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 609 units of BBI stock worth $1,431 on 31 August 2020.
The largest trade he's ever made was buying 330,000 units of Brickell Biotech Inc stock on 10 January 2014 worth over $468,600. On average, Vijay trades about 12,837 units every 61 days since 2003. As of 31 August 2020 he still owns at least 19,680 units of Brickell Biotech Inc stock.
You can see the complete history of Mr. Samant stock trades at the bottom of the page.
Vijay B. Samant is Director of the Company. Mr. Samant served as President and Chief Executive Officer of Vical since November 2000. Prior to joining Vical, he had 23 years of diverse U.S. and international sales, marketing, operations, and business development experience with Merck. From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. Mr. Samant holds a master’s degree in management studies from the Sloan School of Management at MIT, a master’s degree in chemical engineering from Columbia University, and a bachelor’s degree in chemical engineering from the University of Bombay, University Department of Chemical Technology. Mr. Samant was a member of the board of directors of AmpliPhi Biosciences Corporation from 2015 to 2019, a member of the board of directors of Raptor Pharmaceutical Corporation from 2011 to 2014, and a member of the board of directors for BioMarin Pharmaceutical Inc. from 2002 to 2004. Mr. Samant was a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010, a member of the Board of Trustees for the National Foundation for Infectious Diseases from 2003 to 2012, and a member of the Board of Trustees for the International Vaccine Institute in Seoul, Korea from 2008 to 2012.
As the Director of Brickell Biotech Inc, the total compensation of Vijay Samant at Brickell Biotech Inc is $1,464,000. There are no executives at Brickell Biotech Inc getting paid more.
Vijay Samant is 66, he's been the Director of Brickell Biotech Inc since 2019. There are 2 older and 15 younger executives at Brickell Biotech Inc. The oldest executive at Brickell Biotech Inc is Albert Nicholas Marchio II, 69, who is the Chief Financial Officer.
Vijay's mailing address filed with the SEC is C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102, BOULDER, CO, 80301.
Over the last 5 years, insiders at Brickell Biotech Inc have traded over $0 worth of Brickell Biotech Inc stock and bought 584,350 units worth $353,337 . The most active insiders traders include Vijay B Samant, Monica E. Luchi, eGary A Lyons. On average, Brickell Biotech Inc executives and independent directors trade stock every 16 days with the average trade being worth of $51,782. The most recent stock trade was executed by Reginald L Hardy on 23 July 2021, trading 200,000 units of BBI stock currently worth $134,000.
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell's executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell's strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs.
Brickell Biotech Inc executives and other stock owners filed with the SEC include: